The San Jose Biocenter sponsors an afternoon talk on submitting an investigational new drug application to the FDA. From the event description:
“Whether your goal is to develop your pipeline through commercial launch, or partner as early as possible, submitting an IND is a critical early milestone. Even with big pharma and VC firms competing for the most promising compounds, the bar is still quite high and startups are expected to demonstrate a solid plan for achieving IND acceptance to be taken seriously.”
Xconomy readers are eligible to register at the partner network rate. Register here: http://lllind-xcon.eventbrite.com/